Epidemiology and Outcomes of Hospitalized Adults with SARS-CoV-2 Community-Acquired Pneumonia in Louisville, Kentucky

Julio A Ramirez1∗; T’shura Ali2,2; Thomas Chandler1; Stephen Furmanek1; Daniya Sheikh1; Vidyulata Salunkhe1; Steven Gootee3; Mohammad Tahboub1; William A. Mattingly1; Demetra Antimisiaris2; Jiapeng Huang1,3,4,5; Jose Bordon1; Rodrigo Cavallazzi1,6; Paul Schulz7; William P. McKinney2; Dawn Balcom1; Leslie Wolf1; Mark Burns1; Ruth M. Carrico1; Forest Arnold1; and the CERID COVID-19 Study Group1

1 Division of Infectious Diseases, Center of Excellence for Research in Infectious Diseases (CERID), University of Louisville, Louisville, KY, USA; 2 Department of Epidemiology and Population Health, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, USA; 3 Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, USA; 4 Department of Anesthesiology & Perioperative Medicine, University of Louisville, Louisville, KY, USA; 5 Department of Cardiovascular & Thoracic Surgery, University of Louisville, Louisville, KY, USA; 6 Department of Medicine, University of Louisville, Louisville, KY, USA; 7 Norton Healthcare, Louisville, KY, USA

∗j.ramirez@louisville.edu

Recommended Citation: Ramirez JA, Ali T, Chandler T, et al. Epidemiology and outcomes of hospitalized adults with SARS-CoV-2 community-acquired pneumonia in Louisville, Kentucky. Univ Louisville J Respir Infect 2022; 6(1):Article 2. doi: 10.18297/jri/vol6/iss1/2.

Abstract

Background: During the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-2 community-acquired pneumonia (CAP) has been the primary cause of hospitalization. The objective of this study was to evaluate the clinical characteristics and outcomes of 1,013 patients hospitalized with SARS-CoV-2 CAP from September 2020 through March 2021 in Louisville, Kentucky.

Methods: This was a retrospective observational study of 1,013 patients hospitalized with SARS-CoV-2 CAP at eight of the adult hospitals in the city of Louisville from September 2020 through March 2021. Patients with 1) a positive reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2, 2) fever, cough, or shortness of breath, and 3) an infiltrate on chest imaging were defined as having SARS-CoV-2 CAP. Data were abstracted from each hospital’s electronic health record. Descriptive statistics were performed on clinical and epidemiological characteristics of hospitalized patients with SARS-CoV-2 CAP. Demographic characteristics of the study population were compared with census data from the city of Louisville. Data were analyzed by descriptive and inferential statistics using R version 3.4.0.

Results: Of the 1,013 patients hospitalized with SARS-CoV-2 CAP, the median age was 65 years, 53% were males, 24% reported their race as African American or Black, and 6% identified as Hispanic. The most frequent comorbidities were hypertension (73%), obesity (56%), and diabetes (43%). At the time of admission, 60% required supplemental oxygen. The mortality rate was 19% for the total population and 45% for the 359 patients admitted to the intensive care unit (ICU). For each comorbidity, the proportion of hospitalized patients with SARS-CoV-2 CAP was significantly different from the Louisville population (P<0.001). No significant differences were noted in race or ethnicity compared to the city of Louisville.

Conclusions: The elderly, males, and patients with a history of coronary artery disease, cerebrovascular disease, chronic obstructive pulmonary disease, hypertension, diabetes, renal disease, or obesity are overrepresented among hospitalized patients with SARS-CoV-2 CAP compared to the Louisville population. These patients are also more likely to require ICU care and experience worse clinical outcomes, with death occurring in approximately one in every five hospitalizations.

Introduction

Before the COVID-19 pandemic, viral community-acquired pneumonia (CAP) was diagnosed in approximately 30% of adults hospitalized with CAP.[1] The most commonly identified viruses were influenza, rhinovirus, and respiratory syncytial virus (RSV).[2] Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the primary respiratory viral pathogen causing CAP. As the current pandemic progresses, the burden of SARS-CoV-2 CAP is changing, and the clinical characteristics and outcomes of hospitalized adults with SARS-CoV-2 CAP will continue to evolve, especially as new variants emerge, such as the Delta variant. An up-to-date understanding of the type of patients hospitalized with SARS-CoV-2 CAP will be necessary for investigators to develop optimal interventions to combat this infection. To better understand the current epidemiology of SARS-CoV-2 CAP, we evaluated the clinical characteristics and outcomes of 1,013
consecutive patients recently hospitalized with SARS-CoV-2 CAP from September 2020 through March 2021 in the city of Louisville, Kentucky.

Methods

Study design, subjects, and setting

This was a retrospective observational study of 1,013 consecutive patients with a diagnosis of SARS-CoV-2 CAP hospitalized at eight of the nine adult acute care hospitals in the city of Louisville, Kentucky. Hospitalizations between September 2020 and March 2021 were included in this analysis. Patients were followed until hospital discharge or in-hospital death.

Human subjects protection

The study was approved by the Institutional Review Board (IRB) at the University of Louisville Human Subjects Research Protection Program Office (IRB number 20.0257) and by the research offices at each participating hospital. The study was exempt from informed consent.

Study coordinating center

The Center of Excellence for Research in Infectious Diseases (CERID), located at the University of Louisville Division of Infectious Diseases, directed all study operations (CERID.louisville.org). Members of CERID 1) developed the study data collection form and the study database, 2) collected data from hospital electronic medical records, 3) recorded data into the study database, and 4) performed quality control of collected data by initiating and resolving queries. Data were collected and managed using Research Electronic Data Capture (REDCap®) tools hosted at the University of Louisville Division of Infectious Diseases. REDCap® is a secure, web-based software platform designed to support data capture for research studies, providing an intuitive interface for validated data capture.[3] After all data queries were resolved, the study database was locked for data analysis.

Data collection

Patient data were abstracted from hospital electronic medical records. Collected data included patient age, sex, race/ethnicity, body mass index, type of residence, medical and social history, physical examination findings, laboratory findings, chest radiographs and chest computer tomography (CT) findings, medications, intensive care unit (ICU) admission, and need for invasive mechanical ventilation (IMV). The self-reported race variable was categorized as African American/Black, Caucasian/White, and Other. The Other self-reported race category included Asian, American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, and unknown or unspecified; these were grouped together because of small sample sizes. Ethnicity was categorized as Hispanic or non-Hispanic.

Study definitions

SARS-CoV-2 CAP: A patient hospitalized with 1) a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or other respiratory sample(s), 2) fever, cough, or shortness of breath, and 3) evidence of pulmonary infiltrates on chest radiograph or chest CT scan.

SARS-CoV-2 CAP with ARDS: Presence of acute respiratory distress syndrome (ARDS) was defined as bilateral opacities on a chest radiograph or CT scan not fully explained by cardiac failure or fluid overload with PaO\(_2\)/FiO\(_2\) ≤300 on ventilator settings that included positive end-expiratory pressure (PEEP) ≥5 cm H\(_2\)O.[4]

In-hospital mortality: All-cause mortality during hospitalization. Patients transferred to end-of-life palliative care were considered to have expired during hospitalization, and the date of transfer was used as the date of death.

Clinical success: Hospitalized patients who were discharged alive and returned to the residence from which they were admitted.

Clinical presentation

Adapted from the National Institutes of Health guidelines for COVID-19, the clinical presentation of hospitalized patients with SARS-CoV-2 CAP was classified in the following 5 stages:[5]

**Stage 1:** Hospitalized patients with SARS-CoV-2 CAP but no need for supplemental oxygen.

**Stage 2:** Hospitalized patients with SARS-CoV-2 CAP and need for low-flow supplemental oxygen (e.g., low-flow nasal cannula).

**Stage 3:** Hospitalized patients with SARS-CoV-2 CAP and need for high-flow supplemental oxygen or non-invasive ventilation.

**Stage 4:** Hospitalized patients with SARS-CoV-2 CAP and need for invasive mechanical ventilation, but without the presence of ARDS.

**Stage 5:** Hospitalized patients with SARS-CoV-2 CAP, need for invasive mechanical ventilation, and ARDS, defined as having a PaO\(_2\)/FiO\(_2\) of 201–299 (mild ARDS), 101–199 (moderate ARDS), or ≤100 (severe ARDS).
Severity of disease, comorbid burden, and rates of in-hospital mortality

Severity of SARS-CoV-2 CAP at the time of hospitalization was evaluated using two well-established CAP scores, the pneumonia severity index (PSI) score and the CURB-65 score.[6, 7] The Charlson comorbidity index was used to measure the comorbidity burden.[8] Bar charts were used to describe the distribution of scores, as well as the percentage of patients in each category who died.

Geospatial epidemiology

The geomasked location of the home address of each patient with SARS-CoV-2 CAP enrolled in the study was obtained through the US Census Bureau website.[9] A kernel density heatmap was created using each patient’s address at the time of SARS-CoV-2 CAP hospitalization. Areas of elevated relative risk of contracting SARS-CoV-2 CAP based on underlying population density were identified using Kulldorf’s spatial scan statistic.

Cardiac and cardiovascular events

The following cardiac or cardiovascular events that were present at the time of admission or developed during hospitalization were collected: heart failure, cardiac arrest, cardiogenic shock, acute myocardial infarction, pulmonary edema, new arrhythmia, acute worsening of a chronic arrhythmia, cerebrovascular accident, pulmonary embolism, myocarditis, and deep vein thrombosis.

Coinfections

A patient with a microorganism isolated from blood, respiratory, or urine samples in addition to SARS-CoV-2 infection was defined as having a coinfection. Community-acquired coinfections were defined as microorganisms identified during the first 72 hours of hospitalization. Hospital-acquired coinfections were defined as microorganisms identified more than 72 hours after hospital admission.

Clinical outcomes

Binary outcomes evaluated included hospital discharge, need for invasive mechanical ventilation, admission to the ICU, septic shock, ARDS, and death. For those experiencing any of the previously listed events, time-to-event endpoints evaluated included time to hospital discharge alive (length of hospital stay), time to removal of IMV, time to discharge from the ICU, time to first cardiovascular event, time to septic shock, time to development of ARDS, and time to death. Time-to-event data were right-truncated at 30 days.

Statistical analysis

Continuous patient characteristics were summarized as medians and interquartile ranges (IQR), while categorical patient characteristics were summarized as frequencies and percentages. Comparisons of age, race and ethnicity, and comorbidities between the study population and Louisville’s population demographics were performed using one-sample z-tests of proportions, with null values equal to the Louisville proportion. Louisville population data were taken from the 2017 Behavioral Risk Factor Surveillance System (BRFSS) Smart Data database and the 2019 American Community Survey 5-year estimates.[10, 11] In geospatial analysis, the associated likelihood ratio test using Monte Carlo hypothesis testing was performed for Kulldorf’s spatial scan statistic. Time-to-event outcomes were compared using log-rank tests, with Kaplan–Meier curves produced. Median survival times and 95% confidence limits were reported. Analyses were performed using R version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). P-values were two-sided, with statistical significance set at \( P < 0.05 \).

Results

Study population and clinical presentation

A total of 1,013 patients were hospitalized with SARS-CoV-2 CAP. Demographics and comorbidities for hospitalized patients with SARS-CoV-2 CAP are depicted in Table 1.

COVID-19 vaccination coverage

Among the 1,013 patients hospitalized with SARS-CoV-2 CAP, 30 (3%) were vaccinated for COVID-19 prior to hospitalization. All 30 patients were vaccinated with the BNT162b2 (Pfizer–BioNTech) vaccine; seven (23%) received two doses, and 14 (47%) received one dose. The remaining nine patients did not specify their vaccine dose. This study preceded booster vaccine doses. Median time since the last COVID-19 vaccination dose received prior to hospitalization was 11 days (IQR 5, 13), with a range of 2–76 days.

Comparisons of SARS-CoV-2 CAP patients’ race and ethnicity with the Louisville population are shown in Figure 1. There were no statistically significant differences in race and ethnicity between our cohort and the Louisville population.

Comparisons of SARS-CoV-2 CAP patients’ comorbidities with the Louisville population are shown in Figure 2. Every comorbidity was significantly different from the Louisville population.

Stages of clinical presentation at the time of hospital admission are depicted in Figure 3. While the clinical
Figure 1. Comparisons race and ethnicity of hospitalized SARS-CoV-2 CAP patients with the Louisville population with associated $P$-values from hypothesis testing. All data are reported as a percentage of the population for that demographic.

Figure 2. Comparison of rates of comorbidities of hospitalized SARS-CoV-2 CAP patients with rates in the Louisville population with associated $P$-values from hypothesis testing. $P>0.001$ for all comparisons. All data are reported as a percentage of the population for that comorbidity.
Table 1. Patient demographics and medical history of 1,013 patients hospitalized with SARS-CoV-2 community-acquired pneumonia.

|                                 | n (%)   |
|---------------------------------|---------|
| Total n                         | 1,013   |
| Age, years (median [IQR])       | 65 [55, 75] |
| Male sex                        | 532 (53) |
| Race                            |         |
| African American                | 244 (24) |
| White                           | 704 (69) |
| Other                           | 66 (7)   |
| Hispanic                        | 58 (6)   |
| Smoking history                 |         |
| Never                           | 533 (53) |
| Former                          | 396 (39) |
| Current                         | 84 (8)   |
| Hypertension                    | 740 (73) |
| Obesity                         | 571 (56) |
| Diabetes                        | 434 (43) |
| Coronary artery disease         | 216 (21) |
| Renal disease                   | 210 (21) |
| Chronic obstructive pulmonary disease | 192 (19) |
| Obstructive sleep apnea         | 192 (19) |
| Congestive heart failure        | 148 (15) |
| Asthma                          | 124 (12) |
| Cerebrovascular disease         | 110 (11) |
| Neoplastic disease (active or within the last year) | 101 (10) |
| Other immunocompromising condition or therapies | 76 (8) |
| Liver disease (non-cirrhotic)   | 30 (3)   |
| Cirrhosis                       | 15 (1)   |
| Prior myocardial infarction     | 98 (10)  |
| Peripheral vascular disease     | 34 (3)   |
| Dementia                        | 46 (5)   |
| Connective tissue disorder      | 14 (1)   |
| Peptic ulcer disease            | 19 (2)   |
| Hemiplegia                      | 16 (2)   |
| Solid tumor                     |         |
| Localized                       | 72 (7)   |
| Metastatic                      | 25 (2)   |
| Leukemia                        | 12 (1)   |
| Lymphoma                        | 8 (1)    |
| Acquired immunodeficiency syndrome | 1 (0)    |
| Charlson comorbidity index (median [IQR]) | 3 [2, 5] |

Abbreviations: IQR, interquartile range.

presentation of SARS-CoV-2 CAP with no supplemental oxygen requirement (stage 1) was present in 40% of patients at the time of admission, 60% of the patients required some form of supplemental oxygen at hospital admission.

Geospatial epidemiology

The kernel density heatmap of each patient’s home address at the time of hospitalization due to SARS-CoV-2 CAP is depicted in Figure 4.

The age distribution of adults hospitalized with SARS-CoV-2 CAP is depicted in Figure 5. A comparison of the percentage distribution of age groups between adults hospitalized with SARS-CoV-2 CAP and the adult population of Louisville is shown in Figure 6.

Signs and symptoms in patients with SARS-CoV-2 CAP are depicted in Table 2. The most common symptoms reported at admission were dyspnea and cough.

Vital signs and laboratory values for patients hospitalized with SARS-CoV-2 CAP at admission are depicted in Table 3.

Relevant inflammatory markers at the time of hospitalization or first available value are depicted in Table 4.

Medications for in-hospital treatment of adults hospitalized with SARS-CoV-2 CAP are shown in Table 5.
A total of 237 patients had a coinfection with SARS-CoV-2 CAP. The list of patients with community-acquired (n=110) and hospital-acquired (n=127) coinfections is summarized in Table 6. For each type of coinfection, the culture sites were characterized.

Severity of disease, comorbid burden, and associated rates of in-hospital mortality

The severity of SARS-CoV-2 CAP at the time of hospitalization—according to Pneumonia Severity Index and CURB-65 score—and comorbidity burden according to the Charlson Comorbidity Index are depicted in Figures 7A–C; associated rates of death or hospice care per class or score are depicted in Figures 7D–F.

Cardiac and cardiovascular events

The prevalence of cardiac and cardiovascular events in our cohort is depicted in Table 7. The most common event was a new arrhythmia, which was observed in 70 (7%) patients.

Clinical outcomes

Out of 1,013 patients hospitalized with SARS-CoV-2 CAP, 822 (81%) patients were discharged alive, and 191 (19%) patients died or went to hospice care. The median length of hospital stay was 7 days. Time to hospital discharge and time to in-hospital death are depicted in Figures 8A and 8B, respectively. A total of 359 (35%) patients were admitted to the ICU, with 209 ICU admissions occurring on the first day of hospitalization. A total of 223 (22%) patients required invasive mechanical ventilation during their hospitalization. Time to ICU discharge and time to extubation are depicted in Figures 8C and 8D, respectively. Time to the first cardiac or cardiovascular event for the 180 patients who experienced an event is depicted in Figure 8E. During hospitalization, a total of 99 (10%) patients experienced septic shock, and a total of 44 (4%) patients experienced ARDS. Time to septic shock and time to ARDS are depicted in Figures 8F and 8G, respectively.

In-hospital mortality stratified by ICU admission, de-
Figure 4. Kernel density heatmap of residential addresses of patients hospitalized with SARS-CoV-2 CAP. Dotted lines indicate areas with an elevated risk of hospitalization due to SARS-CoV-2 CAP.

mographics, and comorbidities is depicted in Figure 9. Death was observed in 45% of patients who were admitted to the ICU.

Discussion

Findings

The primary findings of our study show that from September 2020 through March 2021, the distribution of race of hospitalized patients with SARS-CoV-2 CAP matches the distribution of race in the city of Louisville, as opposed to what we previously demonstrated in July 2020.[12] In the present study, we observed an increased risk of hospitalization due to SARS-CoV-2 CAP among patients in the western half of the city, which has a higher prevalence of minority populations and has been associated with a lower socioeconomic position.[13]

This population of hospitalized SARS-CoV-2 CAP patients was older, with a median age of 65 years compared to 63 years as reported in March through July 2020.[12] Hypertension remained the most prevalent comorbidity among hospitalized patients with SARS-CoV-2 CAP, which is consistent with findings from a large multicenter study conducted in the United States and recent COVID-19 data published by the Centers for Disease Control and Prevention (CDC).[14, 15] In addition to hypertension, obesity, diabetes, renal disease, coronary artery disease, chronic obstructive pulmonary disease (COPD), and cerebrovascular disease were also shown to have higher prevalence rates among hospitalized patients with SARS-CoV-2 CAP compared to the general Louisville population. Given the comorbid status of hospitalized patients, the median Charlson comorbidity index score was 3 (IQR 2, 5) with an estimated 10-year survival rate of 77%.[7]

During the study period from September 2020 through
March 2021, 30 (3%) hospitalized patients were vaccinated for COVID-19 prior to hospitalization; seven (23%) received two doses, and 14 (47%) received one dose. This study preceded booster vaccine doses. A CDC Morbidity and Mortality Weekly Report study done in 13 jurisdictions found similar results, showing that from April 2021 through July 2021, fully vaccinated people accounted for 14% of COVID-19 hospitalizations.[16] While vaccination rates during the time of the present study were relatively low, there were still a few breakthrough cases that required hospitalization. However, it is difficult to draw conclusions as four of the seven fully vaccinated patients were hospitalized within 2 weeks of their second vaccine dose.

At the time of hospital admission, the majority of patients with SARS-CoV-2 CAP presented with shortness of breath, cough, and fever. Vital signs and laboratory findings during the first 24 hours of hospital admission were within normal ranges except for minor deviations in heart rate, systolic blood pressure, SpO₂/FiO₂, PaO₂/FiO₂, blood urea nitrogen, procalcitonin, D-dimer, C-reactive protein, and interleukin-6. Coinfections were identified in 23% of our SARS-CoV-2 CAP patients. Hospital-acquired and community-acquired coinfections included Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA), and other Staphylococcus species. Studies have shown a general decline in influenza and influenza-like ill-
Figure 7. The distribution of patients hospitalized with SARS-CoV-2 CAP by PSI risk class (orange), CURB-65 score (purple), and Charlson comorbidity index (green) are shown in the top row of the figure. Rates of in-hospital mortality by PSI risk class, CURB-65 score, and Charlson comorbidity index are displayed in the bottom row. Asterisks represents a significant linear association with mortality.
Figure 8. Time-to-event outcomes in days of patients hospitalized with SARS-CoV-2 CAP: A) time to hospital discharge, B) time to in-hospital death, C) time to intensive care unit discharge, D) time to extubation, E) time to first cardiovascular event, F) time to septic shock, G) time to ARDS.
Table 2. Signs and symptoms for patients hospitalized with SARS-CoV-2 CAP.

| Sign                          | n (%)  |
|-------------------------------|--------|
| Total                         | 1,013  |
| Dyspnea                      | 757 (75) |
| Cough                        | 683 (67) |
| Fever or subjective fever    | 518 (51) |
| Fatigue                      | 450 (44) |
| Myalgia                      | 233 (23) |
| Nausea                       | 227 (22) |
| Diarrhea                     | 195 (19) |
| Spumut                       | 166 (16) |
| Chest pain                   | 154 (15) |
| Vomit                        | 128 (13) |
| Headache                     | 125 (12) |
| Confusion                    | 101 (10) |
| Ageusia                      | 91 (9)  |
| Anosmia                      | 78 (8)  |
| Dizziness                    | 61 (6)  |
| Congestion                   | 54 (5)  |
| Sore throat                  | 30 (3)  |
| Rhinorrhea                   | 15 (1)  |
| Hemoptysis                   | 12 (1)  |
| Constipation                 | 9 (1)   |

Table 3. Vital signs and laboratory findings at the time of hospitalization. The third column shows the percentage of patients for whom data were unavailable.

| Vital sign                          | Median [IQR] | % Data missing |
|-------------------------------------|--------------|----------------|
| Total n                             | 1,013        |                |
| Heart rate (beats/min)              | 100.0 [83.0, 111.5] | 0.2 |
| Respiratory rate (breaths/min)      | 23.0 [20.0, 28.0] | 0.2 |
| Systolic blood pressure (mmHg)      | 122.0 [106.0, 139.0] | 0.2 |
| Diastolic blood pressure (mmHg)     | 63.0 [53.0, 74.0] | 0.2 |
| Temperature (°C)                    | 37.2 [36.8, 38.0] | 0.2 |
| \( \text{SpO}_2 / \text{FiO}_2 \)   | 332.1 [230.0, 438.1] | 1.2 |
| \( \text{PaO}_2 / \text{FiO}_2 \)  | 202.8 [101.5, 290.5] | 60.6 |
| White blood cell × 1,000 per uL     | 7.3 [4.8, 11.5] | 0.7 |
| Neutrophils × 1,000 per uL          | 5.8 [3.5, 9.6] | 9.3 |
| Lymphocytes × 1,000 per uL          | 0.8 [0.5, 1.1] | 10.6 |
| Neutrophil/lymphocyte              | 7.4 [4.1, 13.8] | 10.6 |
| Hematocrit (%)                     | 37.9 [33.8, 41.8] | 0.7 |
| Glucose (mg/dL)                    | 135.0 [113.0, 187.0] | 0.7 |
| Blood urea nitrogen (mg/dL)        | 21.0 [14.0, 34.0] | 0.8 |
| Creatinine (mg/dL)                 | 1.1 [0.8, 1.6] | 0.7 |

Abbreviations: IQR, interquartile range.

Table 4. Inflammatory markers at time of hospitalization or first available value. The third column shows the percentage of patients for whom data were unavailable.

| Variable                          | Median [IQR] | % Data missing |
|-----------------------------------|--------------|----------------|
| Total n                           | 1,013        |                |
| Ferritin (ng/dL)                  | 399.0 [190.8, 819.0] | 28.9 |
| Procalcitonin (ug/L)              | 0.2 [0.1, 0.6] | 26.2 |
| Lactate (mmol/L)                  | 1.5 [1.1, 2.0] | 45.2 |
| D-Dimer (ng/mL)                   | 773.0 [351.8, 1498.0] | 28.5 |
| Interleukin-6 (pg/mL)             | 22.1 [10.5, 56.6] | 72.2 |
| C-reactive protein (mg/L)         | 31.8 [8.2, 97.8] | 24 |

Abbreviations: IQR, interquartile range.

The severity of SARS-CoV-2 CAP estimated from the Pneumonia Severity Index, the CURB-65, and the

nesses during the SARS-CoV-2 pandemic, which has been attributed to non-pharmaceutical interventions, such as masking, social distancing, and improved hand hygiene.[17, 18] A large retrospective study published in 2020 showed that hospitalized COVID-19 patients with community- and hospital-acquired coinfections had worse clinical outcomes than patients with SARS-CoV-2 alone, which may be an important consideration in the use of antibiotic therapies.[19]

On the first day of hospital admission, 60% of the patients hospitalized with SARS-CoV-2 CAP required some form of oxygen. Approximately 21% of patients were admitted to the ICU on the first day of hospital admission. Other studies, including the data previously described from March through July 2020, show a high rate of ICU admission on the first day of hospitalization.[12, 20, 21] The severity of SARS-CoV-2 CAP cases at hospital admission may suggest a delay by some patients in seeking medical care.

Some of the most frequently used medications in the treatment of hospitalized patients with SARS-CoV-2 CAP during September 2020 through March 2021 were steroids, remdesivir, and convalescent plasma. We observed an increase in the use of these medications compared to the data we previously described from March through July 2020.[12] There was also a dramatic decline in the use of hydroxychloroquine after the U.S. Food & Drug Administration revoked the emergency use authorization to use hydroxychloroquine and chloroquine to treat COVID-19 in certain hospitalized patients.

The severity of SARS-CoV-2 CAP estimated from the Pneumonia Severity Index, the CURB-65, and the
Table 6. Number of patients with coinfections, including micro-organisms and culture sites, in adults hospitalized with SARS-CoV-2 CAP.

| Organism                          | Total n | Culture site (n)                      |
|-----------------------------------|---------|---------------------------------------|
| **Community-acquired coinfections** |         |                                       |
| Staphylococcus non-aureus         | 25      | Blood culture (22), sputum (1), urine culture (2) |
| *Escherichia coli*                | 16      | Urine culture (15), NP swab (1)       |
| MRSA                              | 12      | Blood culture (5), sputum (4), NP swab (3) |
| MSSA                              | 8       | Blood culture (4), sputum (4)         |
| *Pseudomonas aeruginosa*          | 6       | Sputum (4), urine culture (2)         |
| Other Streptococcus species       | 6       | Blood culture (4), urine culture (2)  |
| *Klebsiella pneumoniae*           | 4       | Sputum (2), urine culture (2)         |
| Influenza A Untyped               | 3       | NP swab (3)                           |
| Morganella species                | 3       | Blood culture (1), urine culture (2)  |
| Proteus species                   | 3       | Blood culture (1), sputum (1), urine culture (1) |
| *Streptococcus pneumoniae*        | 3       | Blood culture (1), BAL (1), urinary antigen (1) |
| Aspergillus species               | 2       | Blood culture (1), BAL (1)            |
| Enterobacter species              | 2       | Urine culture (2)                     |
| Fusobacterium species             | 2       | Blood culture (2)                     |
| Influenza B                       | 2       | NP swab (2)                           |
| *Klebsiella aerogens*             | 2       | Blood culture (1), urine culture (1)  |
| Lactobacillus                     | 2       | Urine culture (2)                     |
| *Streptococcus pyogenes*          | 2       | Blood culture (1), OP swab (1)        |
| *Aerococcus urinae*               | 1       | Urine culture (1)                     |
| Group B Streptococcus agalactiae  | 1       | Blood culture (1)                     |
| *Moraxella osloensis*             | 1       | Blood culture (1)                     |
| **Hospital-acquired coinfections** | 127     |                                       |
| MRSA                              | 23      | Blood culture (3), sputum (15), BAL (2), urine culture (2), NP swab (1) |
| Staphylococcus non-aureus         | 21      | Blood culture (19), sputum (1), urine culture (1) |
| *Escherichia coli*                | 19      | Blood culture (2), sputum (7), BAL (1), urine culture (9) |
| MSSA                              | 13      | Blood culture (2), sputum (11)        |
| *Klebsiella pneumoniae*           | 8       | Blood culture (2), sputum (5), urine culture (1) |
| *Pseudomonas aeruginosa*          | 7       | Sputum (2), BAL (1), urine culture (4) |
| Enterobacter species              | 6       | Blood culture (2), sputum (1), BAL (1), urine culture (2) |
| Stenotrophomonas species          | 4       | Sputum (3), BAL (1)                   |
| Aspergillus species               | 3       | Sputum (2), serology (1)              |
| Citrobacter species               | 3       | Sputum (2), BAL (1)                   |
| *Haemophilus influenzae*          | 3       | Sputum (3)                            |
| Serratia species                  | 3       | Blood culture (2), sputum (1)         |
| *Klebsiella oxytoca*              | 2       | Sputum (2)                            |
| Proteus species                   | 2       | Sputum (1), urine culture (1)         |
| *Pseudomonas non-aeruginosa*      | 2       | Sputum (2)                            |
| Other Streptococcus o species     | 2       | Blood culture (1), sputum (1)         |
| *Achromobacter xylosoxidans*      | 1       | BAL (1)                               |
| Acinetobacter species             | 1       | Sputum (1)                            |
| *Aerococcus sanguinicola*         | 1       | Urine culture (1)                     |
| *Klebsiella variicola*            | 1       | Blood culture (1)                     |
| *Mycobacterium avium*             | 1       | Sputum (1)                            |
| *Streptococcus pyogenes*          | 1       | Blood culture (1)                     |

**Abbreviations:** BAL, bronchoalveolar lavage; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*; NP, nasopharyngeal; OP, oropharyngeal.
Table 7. Cardiac and cardiovascular events in patients hospitalized with SARS-CoV-2 CAP.

| Variable                                      | n (%) |
|-----------------------------------------------|-------|
| New arrhythmia                                | 69 (7 )|
| Cardiac arrest                                | 33 (3) |
| Heart failure                                 | 31 (3) |
| Acute myocardial infarction                   | 29 (3) |
| Pulmonary embolism                            | 23 (2) |
| Acute worsening of chronic arrhythmia         | 15 (1) |
| Pulmonary edema                               | 15 (1) |
| Deep vein thrombosis                          | 15 (1) |
| Cerebrovascular accident                      | 12 (1) |
| Cardiogenic shock                             | 6 (1)  |
| Myocarditis                                   | 1 (<1) |
| Any event                                     | 180 (18) |

Charlson comorbidity index showed a significant linear relationship with in-hospital mortality; as each score or index increased, mortality increased as well. CURB-65 score differentiated risk of death during hospitalization, from 6% risk of death in patients with a score of 0 to 57% risk of death for patients with a score of 5. A Charlson comorbidity index score of 5 was observed in 32% of patients and accounted for 20% of in-hospital mortality. The associated 10-year survival for a Charlson Comorbidity Index score of 5 is 21%, suggesting a poor prognosis for long-term outcomes.[6] The relationship between severity of disease indices and mortality shown in our study makes the utilization of these tools crucial for patient management and prognosis. Similar studies have shown that the PSI, CURB-65, and the Charlson comorbidity index can predict in-hospital mortality; however, validation in SARS-CoV-2 CAP patients remains controversial.[22, 23]

In the present study, we assessed six binary outcomes and seven time-to-event outcomes. Compared to our previously published data from March through July 2020, the mean length of hospital stay remained around 7 days for patients who were discharged alive; however, the in-hospital mortality rate increased from 17% to 19%. In comparison to early pandemic data, there were decreases in ICU admission (39.4% vs. 35.7%), invasive mechanical ventilation use (25.2% vs. 22.2%), development of a cardiovascular event during hospitalization (19% vs. 18%), development of septic shock (13.4% vs. 9.7%), and development of ARDS (15.5% vs. 4.4%). These lower rates show the importance of proper assessment of clinical outcomes of SARS-CoV-2 CAP and therapeutic interventions for ongoing research efforts. Similar findings were noted in studies comparing the clinical outcomes of patients hospitalized early in the pandemic to later, showing significant decreases in IMV use and cardiovascular events and small or nonsignificant increases in mortality.[24-26]

Strengths

The epidemiological data in our study, including demographic characteristics, socioeconomic characteristics, and health behaviors, are derived from a hospital system that serves a population highly representative of the general United States population.[27] Another strength of our study is our inclusion criteria, selecting only SARS-CoV-2 CAP. The common discussion of COVID-19 has focused on cases and the case fatality rate, regardless of organ involvement. Hence, comparing studies becomes more difficult when patients with and without pneumonia are analyzed together. The wide range of clinical outcomes evaluated in our study, including binary and time-to-event outcomes, increases the internal validity of the results. Lastly, the timing of this data collection period (September 2020 through March 2021), coincides with the emergence of the SARS-CoV-2 Delta variant in the US; hence, our findings can help to elucidate the clinical characteristics of this new variant and its differences from earlier variants.

Limitations

There are a few limitations to acknowledge. The results of this retrospective study may not be generalizable to the overall population; patients who presented to the emergency department with COVID-19 but were discharged home or those who did not seek medical attention may have significantly different characteristics to patients hospitalized with COVID-19 pneumonia. Due to the nature of the study, we were not able to collect more detailed information on non-hospitalized patients with COVID-19 in the city of Louisville; therefore, we could not evaluate the risk of hospitalization or the role of severity scores in predicting ambulatory care.

Conclusion

In conclusion, we observed considerable in-hospital mortality, as nearly one in five patients hospitalized
with SARS-CoV-2 CAP died, and nearly one in two patients admitted to the ICU with SARS-CoV-2 CAP died. The elderly, males, and comorbid patients were overrepresented among hospitalized patients with SARS-CoV-2 CAP compared to the Louisville population. These patients were also more likely to require ICU care and had worse clinical outcomes. The most prevalent comorbidities in our population were coronary artery disease, cerebrovascular disease, COPD, hypertension, diabetes, renal disease, and obesity. Future studies of hospitalized patients with SARS-CoV-2 CAP should also collect data on non-hospitalized patients to identify risk factors for hospitalization, as well as conducting analytical studies to examine risk factors and develop new management and treatment strategies for patients hospitalized with SARS-CoV-2 CAP.

Received: October 19, 2021
Accepted: January 26, 2022
Published: February 1, 2022

Copyright: © 2022 The author(s). This original article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding Source: The author(s) received no specific funding for this work.

Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.
References

1. Radovanovic D, Sotgiu G, Jankovic M, et al. An international perspective on hospitalized patients with viral community-acquired pneumonia. Eur J Intern Med 2019; 60:54-70. doi: 10.1016/j.ejim.2018.10.020. PMID: 30401576.

2. File TM. Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults. In: Ramirez JA, Bond S. UpToDate. Waltham, MA: Wolters Kluwer, 2020.

3. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95:103208. doi: 10.1016/j.jbi.2019.103208. PMID: 31078660.

4. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307(23):2526-33. doi: 10.1001/jama.2012.5669. PMID: 22797452.

5. National Institutes of Health. Clinical spectrum of SARS-CoV-2 infection. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed 19 October 2021.

6. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4):243-50. doi: 10.1056/nejm199701233360402. PMID: 8995086.

7. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5):377-82. doi: 10.1136/thorax.58.5.377. PMID: 12728155.

8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.

9. United States Census Bureau. Welcome to Geocoder. Available at: https://geocoding.geo.census.gov/geocoder. Accessed 18 August 2021.

10. Centers for Disease Control and Prevention. Laboratory-confirmed COVID-19-associated hospitalizations. Available at: https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html. Accessed 8 September 2021.

11. Roth GA, Emmons-Bell S, Alger HM, et al. Trends in patient characteristics and COVID-19 in-hospital mortality in the United States during the COVID-19 pandemic. JAMA Netw Open 2021; 4(5):e218828. doi: 10.1001/jamanetworkopen.2021.8828. PMID: 35398933.

12. Artero A, Madrazo M, Fernández-Garcés M, et al. Severity scores in COVID-19 pneumonia: a Multicenter, Retrospective, Cohort Study. J Gen Intern Med 2021; 36(5):1338-45. doi: 10.1007/s11606-021-06626-7. PMID: 3575909.

13. Pott Junior H, Cominetti MR. Comorbidities predict 30-day hospital mortality of older adults with COVID-19. Geriatr Nurs 2021; 42(5):1024-8. doi: 10.1016/j.gerinurse.2021.06.011. PMID: 34268151.

14. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open 2021; 4(3):e210417. doi: 10.1001/jamanetworkopen.2021.0417. PMID: 33666657.

15. Centers for Disease Control and Prevention. Laboratory-confirmed COVID-19-associated hospitalizations. Available at: https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html. Accessed 8 September 2021.
25. Contou D, Fraissé M, Pajot O, Tirolien JA, Mentec H, Plantefève G. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Crit Care 2021; 25(1):3. doi: 10.1186/s13054-020-03449-6. PMID: 33397421.

26. Asghar MS, Yasmin F, Haris A, Nadeem A, Taweesedt PT, Surani S. Comparison of first and second waves of COVID-19 through severity markers in ICU patients of a developing country. J Community Hosp Intern Med Perspect 2021; 11(5):576-84. doi: 10.1080/20009666.2021.1949793. PMID: 34567444.

27. Furmanek SP, Glick C, Chandler T, et al. The city of Louisville encapsulates the United States demographics. Univ Louisville J Respir Infect 2020; 4(2):Article 4. doi: 10.18295/jri/vol4/iss2/4.